Alcoholic Hepatitis Clinical Trial
Official title:
Applicability of Liver Transplantation in Alcoholic Hepatitis
Patients with alcoholic hepatitis non-responsive to steroids have a poor prognosis. Recently
a French-Belgian prospective study has obtained good results (acceptable survival with a low
rate of alcohol recidivism).
The hypothesis of the present study is that carefully selected Spanish patients with
alcoholic hepatitis that do not respond to steroid therapy may have a good survival if they
receive a liver transplant. The expected rate of alcohol recidivism in such a selected
population will be low.
This is a open prospective multicenter study. Nineteen liver transplant units in Spain will
take part in it.
Inclusion criteria for patients:
1. Diagnosis of alcoholic hepatitis (liver biopsy will be advisable).
2. First episode of clinical decompensation of alcoholic liver disease (defined as
jaundice, variceal bleeding, ascites or portal-systemic encephalopathy).
3. Absence of a high risk of alcoholic recidivism (according to De Gottardi, et al).
4. Severe alcoholic hepatitis (ABIC score > 6.71)
5. Informed consent
Exclusion criteria :
1. Age over 65 years.
2. Hepatitis B or C or HIV infections.
3. Uncontrolled bacterial infection
4. Other liver diseases, such as alpha-1-antitrypsin deficiency, primary biliary
cirrhosis, ...
5. Morbid obesity (BMI > 35 kg/m2)
6. Major uncontrolled psychiatric disease
7. Drug addiction (excluding tobacco) in the last two years.
8. Absence of informed consent.
9. Acute-on-chronic liver disease.
10. Paracetamol consumption over 10 grams in the last week.
Criteria for liver transplantation.
1. Absence of response to steroid therapy (Lille score ≥ 0.45 7 days after initiation of
steroid therapy).
2. Adequate social and familiar environment.
3. Complete agreement in the medical staff about the candidate to transplantation.
4. Absence of bacterial or fungal infection.
Three groups of patients will be formed:
Group 1. Patients with severe alcoholic hepatitis and good response to therapy. Group 2.
Patients with severe alcoholic hepatitis and poor response to therapy, that are not
candidates to transplantation.
Group 3. Patients with severe alcoholic hepatitis and poor response to therapy, that are
candidates to transplantation.
A complete follow-up of the patients would be extended to five years. The survival of these
three groups will be compared. Survival of liver transplant recipients should also be
compared with survival of other liver transplant recipients.
Alcohol recidivism should also be studied in all the patients of the study. Sample size
estimation: According to the data published by Mathurin et al, 28 patients treated with
liver transplantation and 28 non-transplanted patients with severe alcoholic hepatitis
should be necessary.
Interim analysis after every 10 transplanted patients should be performed. The study will be
interrupted if the differences in the survivals between groups 2 and 3 reaches a
significance of 0.01. In case this significance is not reached the inclusion of patients
should end when 40 patients are transplanted. This sample size is estimated to be reached in
18-24 months.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04066179 -
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
|
N/A | |
Completed |
NCT03732586 -
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00962442 -
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
|
Phase 3 | |
Not yet recruiting |
NCT06307522 -
MRG-001 in Patients With Alcoholic Hepatitis
|
Phase 2 | |
Recruiting |
NCT05018481 -
HA35 Moderate Alcoholic Hepatitis (AH) Study
|
Early Phase 1 | |
Completed |
NCT04544020 -
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
|
||
Recruiting |
NCT04088370 -
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
|
||
Completed |
NCT04235855 -
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
|
N/A | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT00851981 -
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
|
Phase 2 | |
Completed |
NCT04084522 -
Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT05840640 -
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
|
Phase 4 | |
Recruiting |
NCT03069300 -
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
|
Phase 3 | |
Terminated |
NCT02039219 -
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
|
Phase 2 | |
Completed |
NCT01245257 -
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT02019056 -
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
|
Phase 2 | |
Completed |
NCT00388323 -
Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human
|
N/A | |
Recruiting |
NCT03845205 -
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
|
N/A | |
Recruiting |
NCT03703674 -
GCSF in Alcoholic Hepatitis
|
Phase 4 |